| Jean Frame, | |
|
200 Elizabeth St, Charleston, WV 25311-2119 | |
| (304) 766-7655 | |
| Not Available |
| Full Name | Jean Frame |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse - School |
| Location | 200 Elizabeth St, Charleston, West Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124309281 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WS0200X | Registered Nurse - School | 64069 (West Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jean Frame, 501 22nd St, Dunbar, WV 25064-1711 Ph: () - | Jean Frame, 200 Elizabeth St, Charleston, WV 25311-2119 Ph: (304) 766-7655 |
News Archive
GPC Biotech AG has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for satraplatin in combination with prednisone for patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed.
Prostate cancer often becomes lethal as it spreads to the bones, and the process behind this deadly feature could potentially be turned against it as a target for bone-targeting radiation and potential new therapies.
It has been found that one third of college going American students eventually end up becoming cocaine addicts or have abuse problems with alcohol or prescription medications. Further one third of all college going students between ages 21 and 24 are habitual consumers of energy drinks. A new study has linked these two behaviors and noted that students who take energy drinks on a regular basis are more likely to abuse drugs or alcohol as they grow up. The study was published in the journal Drug and Alcohol Dependence.
Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, has announced that it received a £7.5m milestone payment from GlaxoSmithKline (GSK) as a result of achieving a data milestone in its Phase IIa open label extension trial of GSK2402968 (PRO051), being developed to treat Duchenne Muscular Dystrophy (DMD) under its agreement with GSK. The milestone payment was based upon achievement of a successful safety review, with no serious safety signals observed.
› Verified 7 days ago
April Griffith, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 200 Elizabeth Street, Charleston, WV 25311 Phone: 304-348-7740 | |
Amanda Jordan, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 200 Elizabeth St, Charleston, WV 25311 Phone: 304-348-7770 | |
Carrie Lynn Weber, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 400 Tracy Way, Charleston, WV 25311 Phone: 304-720-0205 | |
Cindy Miller, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 900 Virginia St E Ste 400, Charleston, WV 25301 Phone: 681-313-4759 | |
Teresa Gayle Waugh, RN, CDE Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 3110 Maccorkle Ave Se, Charleston, WV 25304 Phone: 304-388-5555 Fax: 304-355-5560 | |
Linda Powers, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 200 Elizabeth St, Charleston, WV 25311 Phone: 304-348-7740 | |
Emily Moore, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 200 Elizabeth St, Charleston, WV 25311 Phone: 304-766-7655 |